In the TROPION-Lung01 Phase 3 trial, Datopotamab Deruxtecan demonstrated a median overall survival of 14.6 months for patients with advanced nonsquamous non-small cell lung cancer.

Incendia Therapeutics Begins Phase 1c Trial with First Patient for PRTH-101, an Innovative DDR1 Inhibitor.

Viridian Therapeutics Reports Encouraging Topline Results from Phase 3 THRIVE Trial of Veligrotug (VRDN-001) in Thyroid Eye Disease Patients.

Basking Biosciences Administers Initial Dosage to Participants in Phase 2 Study of Reversible Thrombolytic BB-031 for Acute Ischemic Stroke.

TILT Biotherapeutics Unveils TILT-123 Clinical Results After Complete IV Administration at ESMO 2024.

Relay Therapeutics has announced encouraging interim results for RLY-2608, the initial investigational allosteric, pan-mutant, and isoform-selective inhibitor of PI3Kα.

These findings showcase the efficacy of its innovative EVX-B2 mRNA Gonorrhea vaccine candidate in eradicating gonorrhea bacteria through the induction of a specialized immune response.

Terns Pharmaceuticals Reports Successful Phase 1 Results for TERN-601 Daily Oral GLP-1R Agonist in Obesity Treatment.

The IDeate-Lung01 Phase 2 Trial shows Ifinatamab Deruxtecan maintains encouraging objective response rates in patients with advanced-stage small cell lung cancer.

GSK plc (LSE/NYSE: GSK) released encouraging top-line outcomes from MATINEE in adult patients suffering from chronic obstructive pulmonary disease (COPD).

Ventyx Biosciences announced that the initial patient has been administered a dose in a Phase 2a study of VTX3232 for individuals with early-stage Parkinson’s disease.

Cytonics Completes Phase 1 Enrollment for Study on CYT-108, a New Protease Inhibitor, in Knee Osteoarthritis Patients.